Pharmaxis achieves 30% reduction in scar tissue in topical LOX inhibitor in Phase 1C study; extends collaboration with UWA

Pharmaxis’ novel topical drug treatment for scarring has achieved encouraging results from a phase 1c showing marked change in scar composition with 30% reduction in collagen content. The study of LOX inhibitor PXS-6302 is being conducted by the University of Western Australia (UWA) under the leadership of Professor Fiona Wood AM.  The study aims to improve the appearance and function of established scars by tackling the enzyme that plays a critical role in crosslinking collagen fibres in scar formation.

The phase 1c study met its primary safety objective and two secondary biomarker endpoints in patients with established scars, providing first ever proof that LOX inhibition reduces skin collagen.

Read more here.

See Proactive Investors interview with CEO Gary Phillips here.